|
시장보고서
상품코드
2032544
개 아토피 피부염 시장 보고서 : 약제 클래스별, 투여 경로, 유통 채널, 지역별(2026-2034년)Canine Atopic Dermatitis Market Report by Drug Class Type, Route of Administration, Distribution Channel, and Region 2026-2034 |
||||||
세계의 개 아토피 피부염 시장 규모는 2025년에 27억 달러에 이르렀습니다. 향후 IMARC Group은 2026-2034년 CAGR 12.58%로 성장하여 2034년까지 82억 달러에 이를 것으로 예측했습니다.
개 아토피 피부염(CAD)은 꽃가루, 집먼지, 벌레 물림, 풀, 음식물 성분 등의 알레르겐에 의해 유발되는 개의 알레르기성 피부질환입니다. 이는 유전적 소인에 의한 것으로, 일반적으로 생후 6개월에서 3세 사이의 개에게 발병합니다. 주로 복부, 입, 눈, 손가락 사이 피부, 귓바퀴, 수근부, 팔꿈치, 회음부에 증상이 나타납니다. CAD는 과도한 긁힘, 염증 및 발바닥, 겨드랑이, 얼굴 주변의 가려움증 등 다양한 증상을 특징으로 합니다. 치료에는 면역억제제, 단일클론항체, 글루코코르티코이드 등이 사용됩니다. 이들은 경구용, 주사제, 외용제로 투여됩니다. 저먼 셰퍼드, 래브라도, 골든 리트리버, 퍼그에서 그 유병률이 매우 높은 것으로 알려져 있습니다.
개 아토피 피부염 시장 동향 :
세계 반려견의 CAD 발생률 증가는 시장 전망을 밝게 만드는 주요 요인 중 하나입니다. 이는 환경 조건의 변화, 대기 오염 수준의 악화, 알레르겐에 대한 장기적인 노출에 기인하는 것으로 추정됩니다. 또한, 발적, 기름진 피부, 효모 냄새와 같은 CAD의 초기 증상과 징후에 대한 보호자들의 관심과 인식이 높아지면서 시장 성장에 힘을 보태고 있습니다. 또한, 이 질환을 치료하는 데 있어 단일클론항체의 보급도 시장 성장을 가속하고 있습니다. 이 항체는 필요한 면역반응을 유도하고 질병의 진행을 억제하는 데 도움이 됩니다. 이에 따라 동수처리 향상에 전념하는 수의사, 병원, 클리닉 증가도 시장 성장에 긍정적인 영향을 미치고 있습니다. 이 외에도 동물에 대한 인체용 의약품의 적응증 외 사용을 제한하기 위한 다양한 정부 정책의 시행과 수의학 분야의 광범위한 연구개발(R&:D) 등이 시장 성장을 견인할 것으로 예측됩니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문:
- 지금까지 전 세계 개 아토피 피부염 시장은 어떻게 성장해왔으며, 향후 몇 년 동안은 어떻게 변화할 것인가?
- COVID-19는 전 세계 개 아토피 피부염 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 약효군별로 볼 때, 시장은 어떻게 구분되나요?
- 투여경로별 시장 현황은?
- 유통 채널별 시장 현황은?
- 이 산업의 가치사슬에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는?
- 세계 개 아토피 피부염 시장의 구조는 무엇이며 주요 업체는?
- 이 업계의 경쟁은 얼마나 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 개 아토피 피부염 시장
제6장 시장 분석 : 약제 클래스별
제7장 시장 분석 : 투여 경로별
제8장 시장 분석 : 유통 채널별
제9장 시장 분석 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
JHS 26.05.18The global canine atopic dermatitis market size reached USD 2.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 8.2 Billion by 2034, exhibiting a growth rate (CAGR) of 12.58% during 2026-2034.
Canine atopic dermatitis (CAD) is an allergic skin disease in dogs caused by allergens, such as pollens, house dust, insect bites, grass and food ingredients. It is an inherited predisposition that generally affects dogs aged between six months to three years. It commonly affects the ventral abdomen, mouth, eyes, interdigital skin, ear pinnae, carpal, elbow and perineal area of the animals. CAD is characterized by various symptoms, such as excessive scratching, inflammation and itching around paws, underarms and face. It can be treated by immuno-suppressants, monoclonal anatomy and glucocorticoids. They can be administered through oral, injectables and topical medications. It is known to be highly prevalent in German shepherds, Labradors, golden retrievers and pugs.
Canine Atopic Dermatitis Market Trends:
The increasing occurrence of CAD in domesticated dogs across the globe is one of the key factors creating a positive outlook for the market. This can be attributed to the changing environmental conditions, rising air pollution levels and prolonged exposure to allergens. Moreover, the increasing concerns and rising awareness among pet owners regarding early symptoms and signs of CAD, such as redness, greasy skin and yeasty smell, are providing a thrust to the market growth. Additionally, the widespread adoption of monoclonal antibodies for the treatment of the disease is favoring the market growth. These antibodies aid in directing the required immune response and calming the spread of the disease. In line with this, the increasing number of veterinary practitioners, hospitals and clinics dedicated to providing improved care for animals is positively impacting the market growth. Other factors, including the implementation of various government initiatives to restrict the usage of off-label human drugs on animals, along with extensive research and development (R&D) in the field of veterinary sciences, are anticipated to drive the market toward growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global canine atopic dermatitis market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on drug class type, route of administration and distribution channel.
Breakup by Drug Class Type:
- Glucocorticoids
- Immunosuppressants
- Monoclonal Antibody
- Others
Breakup by Route of Administration:
- Topical
- Oral
- Injectable
Breakup by Distribution Channel:
- Veterinary Hospitals
- Pet Clinics
- Pharmacies and Drugstores
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Bimeda Inc., Bioceltix SA, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Toray Industries Inc., Vetoquinol S.A., Virbac and Zoetis Inc.
Key Questions Answered in This Report:
- How has the global canine atopic dermatitis market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global canine atopic dermatitis market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global canine atopic dermatitis market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Canine Atopic Dermatitis Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Class Type
- 6.1 Glucocorticoids
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Immunosuppressants
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Monoclonal Antibody
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Topical
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Oral
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Injectable
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Veterinary Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Pet Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Pharmacies and Drugstores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AB Science
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.2 Bimeda Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Bioceltix SA
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Boehringer Ingelheim International GmbH
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Ceva Sante Animale
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Dechra Pharmaceuticals PLC
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Elanco Animal Health Incorporated
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.8 Phibro Animal Health Corporation
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Toray Industries Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Vetoquinol S.A.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.11 Virbac
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Zoetis Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
- 14.3.1 AB Science
